394,500.00
+7,500.00
+(1.94%)
As of 11:32:23 AM GMT+9. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
74,375,118.66
96,522,928.88
28,806,344.49
38,745,944.02
42,425,842.46
Cost of Revenue
42,194,057.66
65,324,369.40
24,275,249.61
32,956,780.28
23,670,122.04
Gross Profit
32,181,061
31,198,559.48
4,531,094.88
5,789,163.74
18,755,720.42
Operating Expense
--
40,935,397.86
33,904,775.03
20,981,178.11
18,813,889.12
Operating Income
22,764,116.10
-9,736,838.38
-29,373,680.15
-15,192,014.37
-58,168.70
Net Non Operating Interest Income Expense
4,664,899.17
4,520,700.81
3,443,415.42
1,460,954.21
104,622.38
Pretax Income
-5,061,465.89
-3,564,374.99
-9,969,855.06
-10,694,355.83
-17,691,529.37
Tax Provision
8,234.15
17,833.68
108,049.04
893,168.16
583,057.41
Net Income Common Stockholders
-2,910,586
-3,371,764
-8,146,003.03
-6,274,918.06
-15,821,779.56
Basic EPS
-61.26
-65.00
-159.00
-103.33
-209.44
Diluted EPS
-61.26
-65.00
-159.00
-103.33
-209.44
Basic Average Shares
53,124.82
51,873.29
51,232.72
60,725.01
75,541.65
Diluted Average Shares
53,124.82
52,683.81
52,896.12
60,725.01
75,541.65
Total Operating Income as Reported
-5,699,372.87
-9,736,838.48
-29,373,680.27
-15,192,014.48
-58,168.69
Rent Expense Supplemental
--
21,456.50
89,066.28
58,072.40
44,411.01
Total Expenses
51,611,002.56
106,259,767.26
58,180,024.64
53,937,958.39
42,484,011.16
Net Income from Continuing & Discontinued Operation
-2,910,586
-3,371,764
-8,146,003.03
-6,274,918.06
-15,821,779.56
Normalized Income
-2,849,655.26
-4,769,912.42
-7,881,061.76
-3,325,823.89
-15,067,263.79
Interest Income
--
5,191,585.31
3,868,896.24
2,065,615.54
901,406.19
Interest Expense
--
670,884.49
425,480.82
604,661.33
796,783.81
Net Interest Income
4,664,899.17
4,520,700.81
3,443,415.42
1,460,954.21
104,622.38
EBIT
17,923,763.21
-2,893,490.50
-9,544,374.24
-10,089,694.50
-16,894,745.56
EBITDA
17,923,763.21
440,040.09
-6,890,063.96
-7,938,774.29
-15,025,878.30
Reconciled Cost of Revenue
42,194,057.66
65,324,369.40
24,275,249.61
32,956,780.28
23,670,122.04
Reconciled Depreciation
--
3,333,530.59
2,654,310.28
2,150,920.21
1,868,867.26
Net Income from Continuing Operation Net Minority Interest
-2,910,586
-3,371,764
-8,146,003.03
-6,274,918.06
-15,821,779.56
Total Unusual Items Excluding Goodwill
-80,172.03
1,839,668.98
-365,436.23
-3,932,125.56
-1,006,021.03
Total Unusual Items
-80,172.03
1,839,668.98
-365,436.23
-3,932,125.56
-1,006,021.03
Normalized EBITDA
18,003,935.24
-1,399,628.89
-6,524,627.73
-4,006,648.73
-14,019,857.27
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-19,241.29
441,520.56
-100,494.96
-983,031.39
-251,505.26
12/31/2020 - 12/12/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
087010.KQ Peptron, Inc.
90,100.00
+2.50%
141080.KQ LigaChem Biosciences Inc.
110,600.00
+0.55%
028300.KQ HLB Co., Ltd.
89,150.00
-0.17%
358570.KQ GI Innovation, Inc.
15,360.00
-4.71%
6IB.SG Innovent Biologics, Inc.
4.9000
0.00%
005690.KS Pharmicell Co., Ltd.
10,070.00
-0.30%
389650.KQ NEXTBIOMEDICAL
49,300.00
-7.85%
950160.KQ Kolon TissueGene, Inc.
37,000.00
+1.93%
115450.KQ HLB Therapeutics Co.,Ltd.
10,260.00
-0.87%
298380.KQ ABL Bio Inc.
41,350.00
+2.48%